DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

• DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
• The leading companies working in the Esophageal Squamous Cell Carcinoma Market include BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Promising Esophageal Squamous Cell Carcinoma Pipeline Therapies in the various stages of development include Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.
• December 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Tiragolumab and Atezolizumab. The purpose of this study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
• December 2023: Merck Sharp & Dohme LLC announced a study of Phase 3 clinical trials for Pembrolizumab, Lenvatinib, Cisplatin, Oxaliplatin, and Levoleucovorin. The purpose of this study is to assess the efficacy and safety of pembrolizumab plus lenvatinib plus chemotherapy compared with pembrolizumab plus chemotherapy as first-line intervention in participants with metastatic esophageal carcinoma. The primary hypotheses are that pembrolizumab plus lenvatinib plus chemotherapy is superior to pembrolizumab plus chemotherapy with respect to overall survival (OS) and progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR). 

• December 2023: BeiGene announced a study of Phase 2 clinical trials for LBL-007 and Tislelizumab. This is a randomized, open-label study to compare how well LBL-007 works in combination with tislelizumab and chemotherapy versus tislelizumab and chemotherapy when given as the first-line treatment in participants with inoperable locally advanced or metastatic esophageal squamous cell carcinoma (ESCC). 

 

Request a sample and discover the recent advances in Esophageal Squamous Cell Carcinoma Treatment Drugs @ Esophageal Squamous Cell Carcinoma Pipeline Outlook Report

 

In the Esophageal Squamous Cell Carcinoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Esophageal Squamous Cell Carcinoma NDA approvals (if any), and product development activities comprising the technology, Esophageal Squamous Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Esophageal Squamous Cell Carcinoma Overview

Esophageal Squamous Cell Carcinoma is the most common form of esophageal cancer worldwide. Although it is no longer the most common form of esophageal carcinoma in Western societies, ESCC continues to be the most prevalent type of esophageal cancer in the East, representing 90% of all cancers in most Asian, African, and Eastern European countries. Clinical management of ESCC remains challenging and the disease presently lacks approved targeted therapeutics.

 

Find out more about Esophageal Squamous Cell Carcinoma Therapeutics Assessment @ Esophageal Squamous Cell Carcinoma Preclinical and Discovery Stage Products

 

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

• Tislelizumab: BeiGene
• Serplulimab: Shanghai Henlius Biotech

 

Esophageal Squamous Cell Carcinoma Pipeline Therapeutics Assessment

There are approx. 50+ key companies which are developing the Esophageal Squamous Cell Carcinoma therapies. The Esophageal Squamous Cell Carcinoma companies which have their Esophageal Squamous Cell Carcinoma drug candidates in the most advanced stage, i.e. phase III include, BeiGene.

 

DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

 

Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

 

Learn more about the emerging Esophageal Squamous Cell Carcinoma Pipeline Therapies @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment

 

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

• Coverage- Global
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc. and others.
• Esophageal Squamous Cell Carcinoma Pipeline Therapies- Sitravatinib, Tislelizumab, Docetaxel, Irinotecan, SI-B001, Cisplatin, Paclitaxel, and others.

 

Dive deep into rich insights for new drugs for Esophageal Squamous Cell Carcinoma Treatment, Visit @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Executive Summary
3. Esophageal Squamous Cell Carcinoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tislelizumab: BeiGene
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RAPA-201: Rapa Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. SGN-B6A: Seagen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Esophageal Squamous Cell Carcinoma Key Companies
21. Esophageal Squamous Cell Carcinoma Key Products
22. Esophageal Squamous Cell Carcinoma- Unmet Needs
23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers
24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion
25. Esophageal Squamous Cell Carcinoma Analyst Views
26. Esophageal Squamous Cell Carcinoma Key Companies
27. Appendix

 

For further information on the Esophageal Squamous Cell Carcinoma Pipeline therapeutics, reach out to Esophageal Squamous Cell Carcinoma Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market